Introduction
Angiotensin II (Ang II) blocking agentsangiotensin-converting enzyme (ACE) inhibitors and Ang II receptor antagonists (AIIAs) -have been used as antihypertensive and antiproteinuric drugs, attenuating the progression and inducing regression of glomerulosclerosis in different renal diseases in both clinical and experimental studies. [1] [2] [3] Also, ACE-inhibitors have been shown to prevent target-organ damage in hypertension. 4 The mechanisms responsible for the beneficial effects of the ACE-inhibitor on chronic proteinuric nephropathy, diabetic and non-diabetic, are not completely known. [5] [6] [7] [8] [9] The renoprotective effects of the ACE-inhibitor seem to be at least partly related to the blockade of the RAS, decreasing glomerular hypertension and proteinuria, which could be independent of the antihypertensive actions. 8, 10, 11 An increase in the number of mitochondria and an antioxidant effect 4 in animals 12 and decreased production and serum levels of tumour necrosis factor-alpha (TNF-α), transforming growth factorbeta (TGF-β) and C-reactive protein have also been demonstrated in humans and animals treated with these agents, 5, 9, 13, 14 although their roles in the renoprotection were not established. More recently a modulation of plasminogen activator inhibitor-1 (PAI-1) and a decrease in tissue inhibitor of metalloproteinase-1 (TIMP-1) were shown to play an important role in the remodelling of glomerulosclerosis 5. An effect of the ACE-inhibitor on some cellular functions, however, has not been fully studied although a possible influence on intracellular organelles has been suggested in streptozotocin diabetic rats. 7, 9 Lysosomes are multivesicular intracellular organelles rich in hydrolytic enzymes and responsible for the degradation of cellular constituents and macromolecules derived from the extracellular space via endocytosis. The proximal tubular cells process the filtered proteins in the kidney and the inhibition of the lysosomal activity increases the urinary excretion of proteins, 15 an important risk factor for the progression of renal disease. 16 Loss of lysosomal-membrane integrity is associated with some clinically important inflammatory process as documented by the accumulation and labilisation of lysosomes in inflammatory sites. 17 It has been demonstrated that several cellular dysfunctions, degenerative conditions and apoptosis might be related to the labilisation of lysosomal membrane and degradative enzyme leakage. 18 Technical procedures to determine the stability/activity of lysosomal membranes have been used as a sensitive method to evaluate the mechanisms involved in the inflammatory process and the sub cellular damaging effects of drugs. 19, 20 The present study investigates the effect of enalapril, an ACE-inhibitor, on the hepatic and renal lysosomal compartments in adult rats.
Methods
Two groups of Wistar rats weighing 200-300 g, maintained in separate cages at 25˚C with natural illumination and fed with standard chow, were studied. The experimental group (20 animals) received enalapril (Sigma-Aldrich Co., St. Louis, MO), 50 mg/L, in the drinking water. The control group (ten rats) was submitted to the same conditions as the experimental group except for tap water for drinking.
After two weeks of treatment, each animal was sacrificed by cervical trauma, without anaesthetic to avoid interference in the lysosomal compartment. Immediately after the sacrifice, samples of liver and kidney were collected, identified and separately washed in 25 x 10 -2 M saccharose solution and refrigerated at 2-4˚C, then reduced to small fragments, washed in the saccharose solution and suspended in a portion of 1 g of tissue to 10 mL of a saccharose special buffer solution (solution of phosphate buffer 10 -2 M, potassium chloride 2 x 10 -3 M, TRIS (2 -amino-2hydoxymethyl-1,3-propanediol) 2 x 10 -3 M, EDTA 4 x 10 -4 M, and saccharose 25x10 -2 M, adjusted to pH 7.4).
The samples were then homogenised using a Potter-Elvejhem, tissue homogeniser with a Teflon® pestle at a velocity of 250 rpm for a maximum of two minutes.
The homogenates were subjected to refrigerated differential centrifugation, as showed in (figure 1), in order to isolate the subcellular fraction rich in lysosomes.
The pellet containing most of the intact lysosomes was suspended to the same volume of original homogenate, using the buffered solution and was kept at rest for 20 minutes in an icebath, to be centrifuged later on at 20,000 g for 20 minutes, in order to redeposit the intact lysosomes. In order to cause complete rupture of lysosomes, digitonin (4 mM) was used in each set of experiment. The supernatant of each tube was utilised for evaluation of ortophosphoricmonoester phosphohydrolase, (EC 3.1.3.2, acid phosphatase). Although it is possible that there was some mitochondrial contamination of the preparation, acid phosphatase is a marker of lysosome membrane and not found in mitochondria. 15 The results were expressed as specific units of phosphatase activity, one unit being equivalent to the enzymatic activity necessary to the hydrolyse of a micromole of substrate, sodium p-nitro phenyl phosphate, at 37˚C and pH 5.4, during one minute, per ml of total proteins determined by the Folin-phenol technique. 21 The data were expressed as mean±SD.
Comparisons between two groups were done using Student's t-test and a p<0.05 result was considered of statistical significance. 
Results
The kidney and liver lysosomal activities found after the labilising effect of digitonin, in control and enalapril-treated groups, as assessed by the acid phosphates activity, are expressed in (figures 2 and 3).
The lysosomes isolated from kidneys of enalapriltreated rats showed a mean specific activity that was 17.6% higher (p<0.05) than the control group (9.0±0.99 U/mg and 7.65±0.55 U/mg, enalapril and control groups, respectively), measured as specific acid phosphatase activity. The mean specific activity of the components of lysosomal compartment isolated from the livers the enalapril-treated rats was not different to the control group (4.47±0.49 U/mg and 5.55±0.79 U/mg, enalapril and control groups, respectively) as shown in (figure 2).
Discussion
Alterations in the morphology and function of lysosomal membranes can damage their structure with intracellular leakage of the hydrolytic enzymes leading to severe cell damage. 20, 22 In addition, leakage of lysosomal enzymes is strongly associated with inflammatory process. 23 In this regard, Hakala et al. 24 demonstrated abundant immunopositive lysosomal acid lipase and cathepsin D in the extracellular matrix surrounding macrophage-rich atherosclerotic areas in human coronary arteries. These data provide the basis for the use of lysosomal membrane stability as a sensitive biomarker of inflammation and environment stress. 19, 24 Furthermore, decreased lysosomal activity inhibits protein processing by renal tubular cells resulting in increased urinary protein concentration and progression of renal disease. 9, 15 In the experiments digitonin was used to labilise the lysosomes in both groups of animals. 25 26, 27 It is expected that the use of a lysosomal protecting drug would be correlated with lower activity of the enzyme marker, as compared with the control, untreated, group after the addition of digitonin.
In the present studies the effect of enalapril on membrane stability of lysosomes isolated from the kidneys of rats was not demonstrated to be protective, as there was a small difference in the mean specific acid phosphatase activities in the groups of animals, at variance with the findings in the liver. The difference in specific activities of this enzyme between liver and kidney seems to be related to the fact the kidney is much richer in lysosomes than the liver. 17 It is possible that the loss of stability in lysosomal membrane induced by enalapril could be small and apparent only when studying a higher number of the organelle.
The RAS has been implicated in the pathophysiology and in the progression of proteinuric chronic renal diseases and its pharmacological blockade has been shown to attenuate the progression, halt and, even, induce regression of glomerulosclerosis. 6, [28] [29] [30] In addition, a greater beneficial and more effective action on renal diseases has been documented with highdose of enalapril. 5, 28 The use of ACE-inhibitor, like enalapril, or/and AIIA, in diabetic and nondiabetic patients with nephropathies to reduce proteinuria, a powerful predictor of future risk of end-stage renal disease, 16 are at least partly independent of its antihypertensive actions. 3, 10, 29 As well, Rugale et al. 4 Regarding a possible intracellular action, Suzuki et al. 31 showed long-term use of an ACE-inhibitor restores normal lysosomal cathepsin activity in a model of chronic renal failure. Osicka et al. and, more recently, Russo et al. 7, 9, 15 studying renal lysosomal activity by dextran sulphate desulphatation, showed that ramipril, an ACEinhibitor, reduced proteinuria in diabetic and nondiabetic spontaneously hypertensive rats preventing TGF-β induced inhibition of lysosomal activity. Of importance, the observed beneficial effect on lysosomal activity was correlated with decreased urinary albumin excretion. The authors question if the observed protection was related to the effect of the drug on the trafficking of macromolecules.
demonstrated prevention and reversion of the
Contrary to the reports of other authors, 7, 9, 15 in the present studies a protective effect of enalapril on lysosomes was not found. Such variance could be related to the use of isolated lysosomes from normal rats, avoiding mediation of proteinuria, renal function, RAS, glucose levels, blood pressure, to mention just a few. 32 It is suggested therefore, that the mechanisms responsible for the beneficial actions of enalapril, such as regression of glomerulosclerosis and reduction of proteinuria, are not directly related to its effects on the lysosomal membrane, at least at the dose used in the present studies. The observations are consistent with these benefits being pre-dominantly related to the blockage of the RAS. 
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